This trial is testing a new drug for people with cancer that has come back or didn't respond to other treatments. It's the first time this drug is being given to humans.
1 Primary · 5 Secondary · Reporting Duration: Baseline through study completion at up to approximately 31 months
100 Total Participants · 1 Treatment Group
Primary Treatment: STI-6643 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: